产品
编 号：F304405
分子式：C25H39NO3
分子量：401.58
分子式：C25H39NO3
分子量：401.58
产品类型
规格
价格
是否有货
200mg
400
In-stock
500mg
480
In-stock
1g
560
In-stock
5g
1440
In-stock
结构图
CAS No: 282526-98-1
产品详情
生物活性：
Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively.
体内研究：
Cetilistat (3, 10, 30, or 100 mg/kg) reduces intestinal fat absorption by inhibiting pancreatic lipase activity in male SD rats.Cetilistat (4.9, 14.9, or 50.7 mg/kg; mixed into powdered high-fat diet; once a day; for three weeks) shows anti-obesity and antihyperlipidemic effects on DIO F344 rats by reducing intestinal fat absorption.Animal Model:Fifty male SD rats (eight weeks of age)
Dosage:3, 10, 30, or 100 mg/kg
Administration:Orally administered; prepared in 0.5 % methylcellulose (MC) suspension
Result:Dose-dependently reduced AUC 0-6 h of plasma triglyceride induced by oral loading of Intrafat 20%. The effect was statistically significant at 3 mg/kg, reaching 45% reduction, while an almost 90 % reduction was achieved at 100 mg/kg.
Animal Model:Male diet-induced obesity (DIO) F344 rats (five weeks of age)
Dosage:4.9, 14.9, or 50.7 mg/kg
Administration:Administered as food admixture in a high-fat diet; once a day; for three weeks
Result:Significantly and dose-dependently reduced body weight gain compared with control.
体外研究：
Cetilistat inhibits rat pancreatic lipase activity with an IC50 of 54.8 nM. Also, Cetilistat inhibits human pancreatic lipase activity with an IC50 of 5.95 nM, which is 9.2 times more potent than for rat pancreatic lipase.
Cetilistat (ATL-962), an inhibitor of pancreatic lipase, acts as an effective anti-obesity agent. Cetilistat inhibits rat and human pancreatic lipase activity with IC50s of 54.8 nM, and 5.95 nM, respectively.
体内研究：
Cetilistat (3, 10, 30, or 100 mg/kg) reduces intestinal fat absorption by inhibiting pancreatic lipase activity in male SD rats.Cetilistat (4.9, 14.9, or 50.7 mg/kg; mixed into powdered high-fat diet; once a day; for three weeks) shows anti-obesity and antihyperlipidemic effects on DIO F344 rats by reducing intestinal fat absorption.Animal Model:Fifty male SD rats (eight weeks of age)
Dosage:3, 10, 30, or 100 mg/kg
Administration:Orally administered; prepared in 0.5 % methylcellulose (MC) suspension
Result:Dose-dependently reduced AUC 0-6 h of plasma triglyceride induced by oral loading of Intrafat 20%. The effect was statistically significant at 3 mg/kg, reaching 45% reduction, while an almost 90 % reduction was achieved at 100 mg/kg.
Animal Model:Male diet-induced obesity (DIO) F344 rats (five weeks of age)
Dosage:4.9, 14.9, or 50.7 mg/kg
Administration:Administered as food admixture in a high-fat diet; once a day; for three weeks
Result:Significantly and dose-dependently reduced body weight gain compared with control.
体外研究：
Cetilistat inhibits rat pancreatic lipase activity with an IC50 of 54.8 nM. Also, Cetilistat inhibits human pancreatic lipase activity with an IC50 of 5.95 nM, which is 9.2 times more potent than for rat pancreatic lipase.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备